Submit processed tissue block or tissue section mounted on a charged, unstained slide
AHL - Immunohistochemistry
Days Set Up:
Mo - Fr
1 - 2 days
If requested, an interpretive report will be provided All IHC stains will include a positive control tissue
Collection/ Processing Details:
P63 is a member of the P53 family, is expressed in the basal cells of many types of epithelia, including skin, cervix, prostate, and GU tract
P63 is most useful in breast and prostate specimens, in demonstrating the presence of an outer myoepithelial or basal layer in benign glands
Malignant glands of prostate do not show staining with this marker; rarely, malignant breast tumor cells will be focally positive for P63
P63 has been reported as a more sensitive marker than high molecular weight cytokeratin (HMW CK/34 beta E12) in identifying the basal layer of prostatic glands
P63 labels most (81%) squamous cell carcinomas, and therefore can be used with CK5/6 in the identification of a poorly differentiated carcinoma in determining possible squamous epithelial origin (both markers should be positive)
Urothelial carcinomas are often positive for P63 (70%)
A cocktail containing both P63 and P504S (racemase) is also available in our laboratory, for the analysis of prostatic specimens
A panel of P63 and SMMS has been recently recommend as the optimal markers for identifying the myoepithelial layer of breast<
However, remember that P63 can demonstrate a discontinuous layer around DCIS and P63 can also rarely label breast cancer cells
P63 is useful in distinguishing acinic cell carcinoma and metastatic renal cell carcinoma from other salivary gland tumors with clear cell and oncocytic features. It shows patchy staining in many salivary gland tumors including mucoepidermoid carcinomas, pleomorphic adenomas, basal cell adenomas, adenoid cystic carcinomas, oncocytomas, and epithelial-myoepithelial carcinomas. It is negative in acinic cell carcinomas and in metastatic renal cell carcinoma
Barbareschi M. et al: P63, a P53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol 25(8): 1054-1060, 2001.
Kaufmann O. et al: Value of P63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol 2001;116; 823-830.
Shah RB et al: Comparison of the basal cell-specific markers, 34BE12 and P63, in the diagnosis of prostate cancer. Am J Surg Pathol 26(9): 1161-1168, 2002.
Wang BY et al: P63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors. Human Pathol, 33(9), 921-926, 2002.
Werling RW et al: Immunohistochemical distinction of invasive from noninvasive breast lesions; a comparative study of )63 vs. calponin and smooth muscle myosin heavy chain. Am J surg Pathol 27(1): 82-90, 2003.
Bilal H, Handra-Luca A, Bertrand JC, Fouret PJ P63 is expressed in basal and myoepithelial cells of human normal and tumor salivary gland tissues J Histochem Cytochem. 2003 Feb;51(2):133-9.
Sams RN, Gnepp DR P63 expression can be used in differential diagnosis of salivary gland acinic cell and mucoepidermoid carcinomas. Head Neck Pathol. 2013 Mar;7(1):64-8.
Carvalho JC, Thomas DG, McHugh JB, Shah RB, Kunju LP p63, CK7, PAX8 and INI-1: an optimal immunohistochemical panel to distinguish poorly differentiated urothelial cell carcinoma from high-grade tumours of the renal collecting system. Histopathology. 2012 Mar;60(4):597-608.